MedTrace Logo

Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI

NCT04493411 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-07-24

No results posted yet for this study

Summary

This study is designed to prospectively determine the sensitivity, specificity, and diagnostic accuracy of whole-body MRI (WBMRI) with Dual-Echo T2-weighted acquisition for Enhanced Conspicuity of Tumors (DETECT) for the detection of multiple myeloma.

Subjects will undergo WBMRI and fluorodeoxyglucose (FDG) positron emission tomography (PET) for research purposes either at one time point for cross-sectional study or at four time points for longitudinal study: baseline, prior to bone marrow transplant (BMT), prior to maintenance therapy, and post BMT. The results of these imaging procedures will be compared to standard of care whole body x-ray and bone marrow biopsy results.

Conditions

Interventions

PROCEDURE

WBMRI

WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points. 1. Baseline: (before or after 1-2 cycles of induction therapy) 2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy) 3. Between Week 24 - 36 (before starting maintenance therapy) 4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)

PROCEDURE

Positron Emission Tomography/Computed Tomography (PET/CT)

PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points. 1. Baseline: (before or after 1-2 cycles of induction therapy) 2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy) 3. Between Week 24 - 36 (before starting maintenance therapy) 4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Avneesh Chhabra, MD, PhD · UT Southwestern Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2024-04-12
Completion
2024-04-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493411 on ClinicalTrials.gov